Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

The current term sheet is for Brilacidin UP,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 541
Posts 24,586
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:52:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:51:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/13/2019 4:11:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/2/2019 4:29:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2019 9:30:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 10:16:34 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:19:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:33:24 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/10/2019 7:32:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/8/2019 4:05:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/31/2019 4:18:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2019 4:17:16 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/22/2019 12:08:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2019 4:32:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2018 5:02:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:07:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:02:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 7:16:54 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/8/2018 5:03:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/24/2018 7:01:54 AM
KarinCA Member Level  Friday, 05/17/19 12:49:39 PM
Re: TheDane post# 263607
Post # of 274914 
The current term sheet is for Brilacidin UP, but, includes the following that I believe covers Brilacidin OM since it is part of the GI tract and subject to a Right of First Negotiation for rights:

From pr
Quote:
and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications.


https://www.stanfordchildrens.org/en/topic/default?id=managing-mucositis-in-children-90-P02733
Quote:
Mucositis can occur anywhere along the digestive tract from the mouth to the anus. ... Rectal ulcerations or redness ... For oral mucositis:


It is called proctitis by some when presenting anally.

*****

https://en.m.wikipedia.org/wiki/Gastrointestinal_tract
Quote:
Description
The gastrointestinal tract is an organ system within humans and other animals which takes in food, digests it to extract and absorb energy and nutrients, and expels the remaining waste as feces. The mouth, esophagus, stomach and intestines are part of the gastrointestinal tract



Btw, this new term sheet proves that the previous term sheet for Brilacidin OM and IBD is no longer in play since it included IBD.

No guarantees, but, I feel good about this one becoming a signed deal.






In Reply to 'TheDane'
It puzzling why there’s even a question about this. There was no mention of B-OM in the news release. Why would anyone think it’s included in the signed Term Sheet?












To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist